

Treating Breast Cancer in Men

If you've been diagnosed with breast cancer, your cancer care team will discuss your treatment options with you. It's important that you think carefully about each of your choices. Weigh the benefits of each treatment option against the possible risks and side effects.

Local treatments

Some treatments are called *local therapies*, meaning they treat the tumor without affecting the rest of the body. These treatments are more likely to be useful for earlier stage (less advanced) cancers, although they might also be used in some other situations. Types of local therapy used fR5 breast canced iclude:5

Most of the information about treating male breast cancer comes from doctors' experience with treating female breast cancer. Because so few men have breast cancer, it is hard for doctors to study the treatment of male breast cancer patients separately in clinical trials.

Treatment of Breast Cancer in Men, by Stage

Adjuvant therapy

Patients who have no detectable cancer after surgery are often given **treatment to help keep the cancer from coming back**. This is known as *adjuvant therapy*. Even in the early stages of breast cancer, cancer cells may break away from the main breast tumor and begin to spread. These cells can't be felt on a physical exam or seen on x-rays or other imaging tests, and they cause no symptoms. But they can become new tumors in nearby tissues and other organs (and bones). The goal of adjuvant therapy is to kill these hidden cells. Systemic therapy and radiation can both be used as adjuvant therapy.

- A radiation oncologist: a doctor who uses radiation to treat cancer
- A **medical oncologist:** a doctor who uses chemotherapy and other medicines to treat cancer

Many other specialists might be part of your treatment team as well, including physician assistants, nurse practitioners, nurses, psychologists, social workers, nutritionists, genetic counselors, and other health professionals.

Health Professionals Who Are Part of a Cancer Care Team

Making treatment decisions

It's important to discuss all of your treatment options, including their goals and possible side effects, with your doctors to help make the decision that best fits your needs. It's also very important to ask questions if there's anything you're not sure about.

If time permits, it is often a good idea to seek a second opinion. A second opinion can give you more information and help you feel more confident about the treatment plan you choose.

- Questions to Ask Your Doctor About Breast Cancer in Men
- <u>Seeking a Second Opinion</u>

Thinking about taking part in a clinical trial

Clinical trials are carefully controlled research studies that are done to get a closer look at promising new treatments or procedures. Clinical trials are one way to get state-ofthe art cancer treatment. In some cases they may be the only way to get access to newer treatments. They are also the best way for doctors to learn better methods to treat cancer.

If you would like to learn more about clinical trials that might be right for you, start by asking your doctor if your clinic or hospital conducts clinical trials.

<u>Clinical Trials</u>

Considering complementary and alternative methods

You may hear about alternative or complementary methods to relieve symptoms or treat

your cancer that your doctors haven't mentioned. These methods can include vitamins, herbs, and special diets, or other methods such as acupuncture or massage, to name a few.

Complementary methods are treatments that are used **along with** your regular medical care. **Alternative** treatments are used **instead of** standard medical treatment. Although some of these methods might be helpful in relieving symptoms or helping you feel better, many have not been proven to work. Some might even be harmful.

Be sure to talk to your cancer care team about any method you are thinking about using. They can help you learn what is known (or not known) about the method, which can help you make an informed decision.

<u>Complementary and Integrative Medicine</u>

Help getting through cancer treatment

People with cancer need support and information, no matter what stage of illness they may be in. Knowing all of your options and finding the resources you need will help you make informed decisions about your care.

Whether you are thinking about treatment, getting treatment, or not being treated at all, you can still get supportive care to help with pain or other symptoms. Communicating with your cancer care team is important so you understand your diagnosis, what treatment is recommended, and ways to maintain or improve your quality of life.

Different types of programs and support services may be helpful, and they can be an important part of your care. These might include nursing or social work services, financial aid, nutritional advice, rehab, or spiritual help.

The American Cancer Society also has programs and services - including rides to treatment, lodging, and more - to help you get through treatment. Call our Cancer Knowledge Hub at 1-800-227-2345 and speak with one of our caring, trained cancer helpline specialists. Or, if you prefer, you can use our chat feature on cancer.org to connect with one of our specialists.

- Palliative Care
- Programs & Services

Choosing to stop treatment or choosing no treatment at all

For some people, when treatments have been tried and are no longer controlling the cancer, it could be time to weigh the benefits and risks of continuing to try new treatments. Whether or not you continue treatment, there are still things you can do to help maintain or improve your quality of life.

Some people, especially if the cancer is advanced, might not want to be treated at all. There are many reasons you might decide not to get cancer treatment, but it's important to talk to your doctors as you make that decision. Remember that even if you choose not to treat the cancer, you can still get supportive care to help with pain or other symptoms.

If Cancer Treatments Stop Working

The treatment information given here is not official policy of the American Cancer Society and is not intended as medical advice to replace the expertise and judgment of your cancer care team. It is intended to help you and your family make informed decisions, together with your doctor. Your doctor may have reasons for suggesting a treatment plan different from these general treatment options. Don't hesitate to ask your cancer care team any questions you may have about your treatment options.

Surgery for Breast Cancer in Men

- Surgery to remove breast cancer
- Surgery to remove nearby lymph nodes
- Chronic pain after breast surgery
- More information about Surgery

Most men with breast cancer have some type of surgery as part of their treatment. There are different types of breast surgery, and it may be done for different reasons, depending on the situation. For example, surgery may be done to:

- Remove as much of the cancer as possible (breast-conserving surgery or mastectomy)
- Find out whether the cancer has spread to the lymph nodes under the arm (sentinel lymph node biopsy or axillary lymph node dissection)
- Relieve symptoms of advanced cancer

Possible side effects of breast surgery

Aside from post-surgical pain, temporary swelling, and a change in the appearance of the breast, possible side effects of surgery include bleeding and infection at the surgical site, *hematoma* (buildup of blood in the wound), and *seroma* (buildup of clear fluid in the wound).

Surgery to remove nearby lymph nodes

To find out if the breast cancer has spread to axillary (underarm) lymph nodes, one or more of these lymph nodes may be removed and looked at in the lab. This is an important part of figuring out the <u>stage</u>¹ (extent) of the cancer.

Lymph nodes may be removed either as part of the surgery to remove the breast cancer or as a separate operation.

Two types of surgery can be used to remove the lymph nodes:

- Sentinel lymph node biopsy (SLNB): A procedure in which the surgeon removes only the lymph node(s) under the arm to which the cancer would likely spread first. Removing only one or a few lymph nodes lowers the risk of side effects from the surgery.
- Axillary lymph node dissection (ALND): A procedure in which the surgeon removes many lymph nodes from under the arm. ALND is not done as often as it was in the past, but it might still be the best way to look at the lymph nodes in some situations.

Either of these procedures can usually be done at the same time as mastectomy or lumpectomy, but they might also be done in a second operation.

For a **sentinel lymph node biopsy**, the surgeon finds and removes the *sentinel node (or nodes)* — the first lymph node(s) into which a tumor drains, and the one(s) most likely to contain cancer cells if they have started to spread.

To do this, the surgeon injects a substance into the area around the tumor, into the skin over the tumor, or into the tissues just under the areola (the colored area around the nipple). This can be done with either:

- A radioactive substance and/or a blue dye, OR
- A liquid containing iron oxide particles

Lymph vessels will carry these substances into the sentinel node(s) over the next few hours. The sentinel nodes can then be found by:

- Using a special machine to detect either radioactivity or iron oxide particles
- Looking for nodes that have turned blue (or brown, if iron oxide particles were injected)

The doctor then makes an incision (cut) in the skin over the area in the armpit and removes the nodes. These nodes (often 2 or 3) are then looked at in the lab.

The lymph nodes can sometimes be checked for cancer during surgery. If cancer is found in the sentinel lymph node, the surgeon may go on to do a full ALND. If no cancer

thought to be in the range of 20-30% after an ALND, and it is less common after a SLNB. Lymphedema seems to be more common if radiation is given after surgery. Sometimes this starts soon after surgery, but it can take a long time to develop. For some people, the swelling lasts for only a few weeks and then goes away. Other times, the swelling lasts a long time. If your arm is swollen, tight, or painful after lymph node surgery, be sure to tell someone on your cancer care team right away. For more information about ways to prevent or manage lymphedema after breast surgery, see Lymphedema³.

Limited arm and shoulder movement: You may also have limited movement in your arm and shoulder after surgery. This is more common after an ALND than a SLNB. Your doctor may give you exercises to ensure that you do not have permanent problems with movement (a frozen shoulder).

Some patients notice a rope-like structure that begins under the arm and can extend down toward the elbow. This, sometimes called *axillary web syndrome* or *lymphatic cording.* It is more common after an ALND than SLNB. Symptoms might not appear for weeks or even months after surgery. It can cause pain and limit movement of the arm and shoulder. This often goes away without treatment, although some people seem to find physical therapy helpful.

Numbness: Numbness of the skin of the upper, inner arm is another common side effect because the nerve that controls sensation here travels through the lymph node area.

Chronic pain after breast surgery

Some patients have problems with nerve (neuropathic) pain in the chest wall, armpit, and/or arm after surgery that doesn't go away over time. This is called post-mastectomy pain syndrome (PMPS) because it was first described in women who had mastectomies, but it occurs after breast-conserving therapy, as well.

PMPS is thought to be linked to damage done to the nerves in the armpit and chest during surgery. But the causes are not known. Between 20% and 30% of women develop symptoms of PMPS after surgery. It isn't clear how common this is in men after breast cancer surgery. It seems to be more common in younger patients, those who had a full ALND (not just a SLNB), and those who were treated with radiation after surgery. Because ALNDs are done less often now, PMPS is less common than it once was.

- Pain and tingling in the chest wall, armpit, and/or arm
- Pain in the shoulder or surgical scar
- Numbness
- Burning or shooting pain
- A "pins and needles" sensation
- Severe itching

Most patients with PMPS say that their symptoms are not severe, but PMPS can cause you to not use your arm the way you should, and over time you could lose the ability to use it normally. Tell your doctor if you are having pain or other symptoms of PMPS. Nerve pain requires different treatment from other types of pain. See <u>Cancer Pain</u>⁴ for more information.

More information about Surgery

More information about radiation therapy

Some men with breast cancer will need radiation, often in addition to other treatments. The recommendations for radiation therapy in men with breast cancer is largely taken from those for female breast cancer because not enough studies have been done in men. The need for radiation depends on what type of surgery you had or whether your cancer has spread to the lymph nodes or somewhere else in your body. Tumors that are large or involve the skin might also need radiation. You could have just one type of radiation, or a combination of different types.

Radiation therapy is treatment with high-energy rays (such as x-rays) or particles that destroy cancer cells. The most common type of radiation therapy for men with breast cancer is called *external beam radiation*. A machine focuses the radiation on the area affected by the cancer.

When might radiation therapy be used?

Not all men with breast cancer need radiation therapy, but it may be used in several situations:

- After breast-conserving surgery (BCS), to help lower the chance that the cancer will come back in the remaining breast tissue or nearby lymph nodes. Radiation is needed less often for men with breast cancer than it is for women, mainly because breast-conserving surgery (BCS) isn't done as much.
- After a mastectomy, especially if the cancer is larger than 5 cm (about 2 inches), attached to the skin, or if cancer is found in the lymph nodes.
- If cancer has spread to other parts of the body, such as the bones or brain.

Which areas need radiation depends on whether you had a mastectomy or breastconserving surgery (BCS) and whether or not the cancer has reached nearby lymph nodes.

- If you had a mastectomy and no lymph nodes had cancer, radiation is focused on the chest wall, the mastectomy scar, and anywhere drains had been placed after surgery.
- If you had BCS, you will most likely have radiation to the entire breast (called whole breast radiation), and an extra boost of radiation to the area in the breast where the cancer was removed (called the tumor bed) to help prevent it from coming back in that area. The boost is often given after the treatments to the whole breast have

Your health care team may advise you to avoid exposing the treated skin to the sun because it could make the skin changes worse. Most skin changes get better within a few months. Changes to the breast tissue usually go away in 6 to 12 months, but it can take longer.

External beam radiation therapy can also cause side effects later on:

- Radiation to the breast or chest wall can sometimes damage some of the nerves to the arm. This is called **brachial plexopathy** and can lead to numbness, pain, and weakness in the shoulder, arm, and hand.
- Radiation to the underarm lymph nodes can cause lymphedema, a type of pain and swelling in the arm or chest.
- In rare cases, radiation therapy may weaken the ribs, which could lead to a fracture.
- In the past, parts of the lungs and heart were more likely to get some radiation, which could lead to long-term damage of these organs. Modern radiation therapy equipment allows doctors to better focus the radiation beams, so these problems are rare today.
- A very rare complication of radiation to the breast or chest wall is the development of another cancer called an angiosarcoma.

More information about radiation therapy

To learn more about how radiation is used to treat cancer, see Radiation Therapy

Lippincott-Williams & Wilkins; 2014.

Jardell P, Vignot S, Cutuli B, et al. Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review. *Anticancer Research*. 2018 (*38*): 23-31.

Khan A and Haffty BG. Chapter 42: Postmastectomy Radiation Therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. *Diseases of the Breast*. 5th ed. Philadelphia: Wolters Kluwer Health; 2014.

Morrow M, Burstein HJ, Harris JR. Chapter 79: Malignant Tumors of the Breast. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

Morrow M and Harris JR. Chapter 35: Breast-Conserving Therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. *Diseases of the Breast*. 5th ed. Philadelphia: Wolters Kluwer Health; 2014.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Breast Cancer. Version 3.2017. Accessed at www.nccn.org on January 18 2018.

Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. *J Natl Cancer Inst.* 2002;94:1143–1150.

Wolff AC, Domchek SM, Davidson NE, Sacchini V, McCormick B. Chapter 91: Cancer of the Breast. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, Pa: Elsevier; 2014.

Last Revised: April 27, 2018

Chemotherapy for Breast Cancer in Men

- When is chemotherapy used?
- Which chemotherapy drugs are used for breast cancer?
- How is chemotherapy given?
- Possible side effects of chemotherapy

More information about chemotherapy

Chemotherapy (chemo) is treatment with cancer-killing drugs that may be given intravenously (injected into your vein) or by mouth. The drugs travel through the bloodstream to reach cancer cells in most parts of the body. Occasionally, chemo might be given directly into the spinal fluid which surrounds the brain and spinal cord.

When is chemotherapy used?

Not all men with breast cancer will need chemo, but there are several situations in which chemo might be recommended:

After surgery (adjuvant chemotherapy): When treatment is given to patients who have no evidence of cancer after surgery, it is called *adjuvant therapy*. Adjuvant chemo is used to try to kill any cancer cells that might have been left behind or have spread but can't be seen, even on <u>imaging tests</u>¹. If these cells were allowed to grow, they could form new tumoOa008 40.01 11.tg /Gpiig 0 0 place/Gpiinally, cheAapy):

benefit from chemo after breast surgery. See <u>How is Breast Cancer in Men Classified?</u>² for more information.

Which chemotherapy drugs are used for breast cancer?

In most cases (especially as adjuvant or neoadjuvant treatment), chemo is most effective when combinations of drugs are used. Today, doctors use many different combinations, and it's not clear that any single combination is clearly the best.

The most common drugs used for adjuvant and neoadjuvant chemo include:

- Anthracyclines, such as doxorubicin (Adriamycin) and epirubicin (Ellence)
- Taxanes, such as paclitaxel (Taxol) and docetaxel (Taxotere)
- 5-fluorouracil (5-FU)
- Cyclophosphamide (Cytoxan)
- Carboplatin (Paraplatin)

Most often, combinations of 2 or 3 of these drugs are used.

Chemo drugs useful in treating breast cancer that has spread include:

- Taxanes, such as paclitaxel (Taxol), docetaxel (Taxotere), and albumin-bound paclitaxel (Abraxane)
- Anthracyclines (Doxorubicin, pegylated liposomal doxorubicin, and Epirubicin)
- Platinum agents (cisplatin, carboplatin)
- Vinorelbine (Navelbine)
- Capecitabine (Xeloda)
- Gemcitabine (Gemzar)
- Ixabepilone (Ixempra) Albumin-bound paclitaxel (nab-paclitaxel or Abraxane)
- Eribulin (Halaven)

Although drug combinations are often used to treat early breast cancer, advanced breast cancer more often is treated with single chemo drugs. Still, some combinations, such as paclitaxel plus carboplatin, are commonly used to treat advanced breast cancer.

For cancers that are <u>HER2-positive</u>³ one or more drugs that target HER2 may be used with chemo. See <u>Targeted Therapy for Breast Cancer in Men</u> for more information about these drugs.

How is chemotherapy given?

Chemo drugs for breast cancer are typically given into a vein (IV), either as an injection over a few minutes or as an infusion over a longer period of time. This can be done in a doctor's office, chemotherapy clinic, or in a hospital.

Often, a slightly larger and sturdier IV is required in the vein system to administer chemo. They are known as <u>central venous catheters</u>⁴ (CVCs), central venous access devices (CVADs), or central lines. They are used to put medicines, blood products, nutrients, or fluids right into your blood. They can also be used to take out blood for testing.

Many different kinds of CVCs are available. The 2 most common types are the port and the PICC line. For breast cancer patients, the central line is typically placed on the opposite side of the breast that had surgery.

Doctors give chemo in cycles, with each period of treatment followed by a rest period. Chemo begins on the first day of each cycle, but the schedule varies depending on the drugs used. For example, with some drugs, the chemo is given only on the first day of the cycle. With others, it is given every day for 14 days, or weekly for 2 weeks. Then, at the end of the cycle, the schedule of chemo repeats to start the next cycle.

Cycles are most often 2 or 3 weeks long, but they vary according to the specific drug or combination of drugs. Some drugs are given more often. Adjuvant and neoadjuvant chemo is often given for a total of 3 to 6 months, depending on what drugs are used. Treatment is often longer for advanced breast cancer, and is based on how well it is working and what side effects you have.

Dose-dense chemotherapy: Doctors have found that giving the cycles of certain chemo agents closer together can lower the chance that the cancer will come back and improve survival in some patients. This usually means giving the same chemo that is normally given, but giving it every 2 weeks instead of every 3 weeks. A drug (growth factor) to help boost the white blood cell count is given after the chemo to make sure the white blood cell count returns to normal in time for the next cycle. This approach can be used for both adjuvant and neoadjuvant chemo. It can lead to more problems with low blood counts, though, so it isn't for everyone.

Possible side effects of chemotherapy

Chemo drugs attack cells that are dividing quickly, which is why they work against cancer cells. But other cells in the body, such as those in the bone marrow, the lining of

the mouth and intestines, and the hair follicles, also divide quickly. These cells are likely to be affected by chemo too, which can lead to side effects. Some men have many side effects while other men may have few.

The side effects of chemotherapy depend on the type of drugs, the amount taken, and the length of treatment. Some of the most common possible side effects include:

- Hair loss
- Mouth sores
- Loss of appetite (or increased appetite)
- Nausea and vomiting
- Low blood cell counts

Chemo can affect the blood-forming cells of the bone marrow, which can lead to:

- Increased chance of infections (from low white blood cell counts)
- Easy bruising or bleeding (from low blood platelet counts) Fatigue (from low red blood cell counts or other reasons)

also carefully control the doses and watch for symptoms of heart problems, and may repeat the heart test to monitor heart function during treatment. If the heart function begins to worsen, treatment with these drugs will be temporarily or permanently stopped. Still, in some people, signs of damage might not appear until months or years after treatment stops. Damage from these drugs happens more often if other drugs that can cause heart damage (such as those that target HER2) are used also, so doctors are more cautious when these drugs are used together.

Hand-foot syndrome: Certain chemo drugs, such as capecitabine and liposomal doxorubicin, can irritate the palms of the hands and the soles of the feet. This is called *hand-foot syndrome*. Early symptoms include numbness, tingling, and redness. If it gets worse, the hands and feet can become swollen, uncomfortable, or even painful. The skin may blister and peel. There is no specific treatment, although some creams or steroids given before chemo may help. These symptoms gradually get better when the drug is stopped or the dose is lowered. The best way to prevent severe hand-foot syndrome is to tell your doctor when early symptoms come up, so that the drug dose can be changed or other medications can be given .

Chemo brain: There is very little research on chemo brain in men, but many women who are treated for breast cancer report a slight decrease in mental functioning. There may be some long-lasting problems with concentration and memory. Although many women have linked this to chemo, it also has been seen in women who did not get chemo as a part of their treatment. Also, most women do function well after chemotherapy. In studies of chemo brain as a side effect of treatment, the symptoms most often go away within a few years. Even though most research was done in women, there's no reason to expect any differences in men being treated for breast cancer.

Increased risk of leukemia: Very rarely, certain chemo drugs can cause diseases of the bone marrow such as <u>myelodysplastic syndrome⁵</u> or even <u>acute myeloid leukemia⁶</u>, a cancer of white blood cells. When this happens it is usually within 10 years of treatment. For most men though, chemo's benefits of helping to prevent breast cancer from coming back or extending life are likely to far exceed the risk of this serious but rare complication.

Feeling unwell or tired: Many people do not feel as healthy after chemotherapy as they did before. There is often a residual feeling of body pain or achiness and a mild loss of physical functioning. These may be very subtle changes that happen slowly over time.

Fatigue is often another common (but often overlooked) problem for those who have had chemo. This may last up to several years. It can often be helped, so it is important

to let your doctor or nurse know about it. Exercise, naps, and conserving energy may be recommended. If there are problems with sleep, these can be treated. Sometimes there is depression, which may be helped by counseling and/or medicines.

More information about chemotherapy

For more general information about how chemotherapy is used to treat cancer, see <u>Chemotherapy</u>⁷.

To learn about some of the side effects listed here and how to manage them, see <u>Managing Cancer-related Side Effects</u>⁸.

Hyperlinks

- 1. <u>www.cancer.org/cancer/diagnosis-staging/tests/imaging-tests/imaging-radiology-</u> tests-for-cancer.html
- 2. <u>www.cancer.org/cancer/types/breast-cancer-in-men/detection-diagnosis-</u> <u>staging/classifying.html</u>
- 3. <u>www.cancer.org/cancer/types/breast-cancer-in-men/detection-diagnosis-</u> <u>staging/classifying.html</u>
- 4. <u>www.cancer.org/cancer/managing-cancer/making-treatment-decisions/tubes-lines-ports-catheters.html</u>
- 5. <u>www.cancer.org/cancer/types/myelodysplastic-syndrome.html</u>
- 6. <u>www.cancer.org/cancer/types/acute-myeloid-leukemia.html</u>
- 7. <u>www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy.html</u>
- 8. www.cancer.org/cancer/managing-cancer/side-effects.html

References

Callahan RD and Ganz PA. Chapter 52: Long-Term and Late Effects of Primary Curative Intent Therapy: Neurocognitive, Cardiac, and Secondary Malignancies. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. *Diseases of the Breast*. 5th ed. Philadelphia: Wolters Kluwer Health; 2014.

Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J Clin Oncol*

Wolff AC, Domchek SM, Davidson NE, Sacchini V, McCormick B. Chapter 91: Cancer of the Breast. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, Pa: Elsevier; 2014.

Last Revised: April 27, 2018

Hormone Therapy for Breast Cancer in Men

- What types of drugs are used in hormone therapy?
- Orchiectomy (castration)
- Possible side effects of hormone therapy
- More information about hormone therapy

Hormone therapy (sometimes called endocrine therapy) is a way to treat cancer by using hormones or drugs or other treatments that affect hormones. Hormone therapy is a form of systemic therapy, meaning it can reach nearly all parts of the body.

Hormone therapy can be used after surgery (adjuvant therapy) to help lower the risk of cancer coming back, or before surgery (neoadjuvant treatment). It can also be used to

Tamoxifen and toremifene

These drugs are known as **selective estrogen receptor modulators (SERMs)**. They

symptoms of a DVT or PE.

• Rarely, tamoxifen has been associated with **strokes** in post-menopausal women. The risk in men is not clear. Tell your doctor if you have a sudden severe headache, confusion, or trouble speaking or moving.

Tamoxifen may also increase the risk of **heart attacks** in some people, although this link is not clear.

Luteinizing hormone-releasing hormone (LHRH) analogs and anti-androgens

In men, **LHRH analogs** such as leuprolide (Lupron) and goserelin (Zoladex) affect the pituitary gland, which regulates testosterone production in the testicles. These drugs cause the pituitary gland to turn off production of testosterone by the testicles, leading to lower testosterone levels. They are given as shots either monthly or every few months. These drugs may be used by themselves, or combined with aromatase inhibitors or anti-androgens to treat advanced breast cancer in men.

Anti-androgens such as flutamide and bicalutamide work by blocking the effect of male hormones on breast cancer cells. These drugs are taken daily as pills.

Megestrol

Megestrol(Megace) is a progesterone-like drug. It is unclear how it stops cancer cells from growing, but it appears to compete for hormone receptor sites in the cells. This is an older drug that is usually reserved for men who are no longer responding to other forms of hormone therapy. Megestrol may **increase the risk for blood clots** and **frequently causes weight gain** by increasing appetite.

Orchiectomy (castration)

Surgical removal of the testicles (orchiectomy) is another way to regulate hormones that might affect breast cancer growth. Removing the testicles greatly lowers the levels of testosterone and other androgens (male hormones). Most male breast cancers have androgen receptors that may cause the cells to grow. Androgens can also be converted into estrogens in the body.

Orchiectomy shrinks most male breast cancers, and it may help make other treatments like tamoxifen more likely to work.

This was once a common treatment for breast cancer in men, but it is now used less often because medicines such as LHRH analogs can now be used to lower androgen levels.

Possible side effects of hormone therapy

Although some of these drugs have unique side effects (see descriptions above), in general they can cause **loss of sexual desire, trouble getting erections, weight gain, hot flashes,** and **mood swings.** Be sure to discuss any such side effects with

your cancer care team because there may be ways to treat them.

More information about hormone therapy

To learn more about how hormone therapy is used to treat cancer, see $\frac{\text{Hormone}}{\text{Therapy}^1}$.

To learn about some of the side effects listed here and how to manage them, see <u>Managing Cancer-related Side Effects</u>².

Hyperlinks

- 1. www.cancer.org/cancer/managing-cancer/treatment-types/hormone-therapy.html
- 2. <u>www.cancer.org/cancer/managing-cancer/side-effects.html</u>

References

Cardoso F, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. *Annals of Oncology* 0: 1–13, 2017.

Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet.* 2013;381:805-816. Erratum in: *Lancet.* 2013 Mar 9;381(9869):804.

Dimitrov NV, Colucci P, Nagpal S. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer. *Oncologist.* 2007;12-798–807.

Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D, Pizzuti L, Sergi D, Barba M, Maugeri-Saccà M. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. *Breast Cancer Res Treat*. 2013 Aug;141(1):119-23. Epub 2013 Aug 28.

Giordano SH. A review of the diagnosis and management of male breast cancer. *Oncologist.* 2005;10: 471–479.

Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN. Adjuvant systemic therapy for male breast carcinoma. *Cancer*. 2005 Dec

1;104(11):2359-64.

Gray RG, Rea D, Handley K, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. *J Clin Oncol* (Meeting Abstracts) June 2013 vol. 31 no. 18_suppl 5.

Jain S and Gradishar WJ. Chapter 61: Male Breast Cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. *Diseases of the Breast*. 5th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 2014.

Losurdo A et al. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature. *Critical Reviews in Oncology/Hematology* 113 (2017) 283–291.

PDQ Adult Treatment Editorial Board. Male Breast Cancer Treatment (PDQ®): Health Professional Version. 2017 Dec 15. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. Available from: https://www-ncbinlm-nih-gov.ezproxyhost.library.tmc.edu/books/NBK65792/. Accessed Jan 10, 2018.

Stearns V and Davidson NE. Chapter 45: Adjuvant Chemo Endocrine Therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. *Diseases of the Breast*. 5th ed. Philadelphia: Wolters Kluwer Health; 2014.

Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G, Zografos G, Bartsch R. Fulvestrant and male breast cancer: a case series. *Ann Oncol.* 2013 Jan;24(1):265-6.

Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos MA, Bartsch R. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. *Br J Cancer*. 2013 Jun 11;108(11):2259-63. Epub 2013 May 30.

Last Revised: January 31, 2023

Targeted Drug Therapy for Breast Cancer in Men

As researchers have learned more about changes in cancer cells that cause them to grow out of control, they've developed new types of drugs that target some of these cell changes. These targeted drugs work differently from chemotherapy (chemo) drugs.

Targeted drugs sometimes work even when chemo drugs do not. Some targeted drugs can help other types of treatment work better. Targeted drugs also tend to have different side effects than chemo.

Several targeted drugs have been approved for use in treating breast cancer, although using these drugs in men is often based largely on how well they work in women.

- Targeted therapy for HER2-positive breast cancer
- Targeted therapy for hormone receptor-positive breast cancer
- Targeted therapy for men with BRCA mutations
- Targeted therapy for triple-negative breast cancer
- More information about targeted therapy

Targeted therapy for HER2-positive breast cancer

In some men with breast cancer, the cancer cells have too much of a growth-promoting protein known as HER2 (or HER2/neu) on their surface. These cancers, known as *HER2-positive breast cancers*, tend to grow and spread more aggressively.

Different types of drugs have been developed that target the HER2 protein.

Monoclonal antibodies

Monoclonal antibodies are man-made versions of immune system proteins (antibodies) that are designed to attach to a specific target. In this case, they attach to the HER2 protein on cancer cells, which can help stop the cells from growing.

Trastuzumab (Herceptin, other brand names¹): Trastuzumab can be used to treat both early-stage and advanced breast cancer. This drug is often given with chemo, but it might also be used alone (especially if chemo alone has already been tried). When started before (neoadjuvant) or after (adjuvant) surgery to treat early breast cancer, this drug is usually given for 6 months to a year. For advanced breast cancer, treatment is often given for as long as the drug is helpful. This drug is given into a vein (IV).

Another form of trastuzumab, called **trastuzumab and hyaluronidase injection (Herceptin Hylecta)**, is also available. It is given as a subcutaneous (under the skin) shot over a few minutes.

Pertuzumab (Perjeta): This monoclonal antibody can be given with trastuzumab and chemo, either before or after surgery to treat early-stage breast cancer, or to treat

Lapatinib (Tykerb): This drug is a pill taken daily. Lapatinib is used to treat advanced breast cancer, typically along with the chemo drug capecitabine or with certain hormone therapy drugs.

Neratinib (Nerlynx): This kinase inhibitor is a pill taken daily. Neratinib is used to treat early-stage breast cancer after completing one year of trastuzumab, and it is usually given for one year. It can also be given along with the chemo drug capecitabine to treat people with metastatic disease, typically after at least 2 other anti-HER2 targeted drugs have been tried.

Tucatinib (Tukysa): This kinase inhibitor is taken as pills, typically twice a day. Tucatinib is used to treat advanced breast cancer, after at least one other anti-HER2 targeted drug has been tried. It is typically given along with trastuzumab and the chemo drug capecitabine.

Side effects of HER2 targeted drugs

The side effects of HER2 targeted drugs are often mild, but some can be serious. Discuss what you can expect with your doctor.

The monoclonal antibodies and antibody-drug conjugates can sometimes cause **heart damage** during or after treatment. This can lead to **congestive heart failure**. For most (but not all) people, this effect lasts a short time and gets better when the drug is stopped. The risk of heart problems is higher when these drugs are given with certain chemo drugs that also can cause heart damage, such as doxorubicin (Adriamycin) and epirubicin (Ellence). Because these drugs can cause heart damage, doctors often check your heart function (with an echocardiogram or a MUGA scan) before treatment, and regularly while you are taking the drug. Let your doctor know if you develop symptoms such as **shortness of breath**, **leg swelling**, and **severe fatigue**.

Lapatinib, neratinib, tucatinib, and the combination of pertuzumab with trastuzumab can cause **severe diarrhea**, so it's very important to let your health care team know about any changes in bowel habits as soon as they happen.

Lapatinib and tucatinib can also cause **hand-foot syndrome**, in which the hands and feet become sore and red, and may blister and peel.

Lapatinib, neratinib, and tucatinib can cause **liver problems**. Your doctor will do blood tests to check your liver function during treatment. Let your health care team know right away if you have possible signs or symptoms of liver problems, such as itchy skin, yellowing of the skin or the white parts of your eyes, dark urine, or pain in the right upper belly area.

Fam-trastuzumab deruxtecan (Enhertu) can cause **serious lung disease** in some people. In some cases this might even be life threatening. It's very important to let your doctor or nurse know right away if you're having symptoms such as coughing, wheezing, trouble breathing, or fever.

Targeted therapy for hormone receptor-positive breast cancer

In about 9 out of 10 men with breast cancer, the breast cancer cells have proteins (receptors) on the outside that can attach to hormones, like estrogen or progesterone, to help them grow. These are called **hormone receptor-positive (HR-positive) breast cancers**. Sometimes they are called estrogen receptor-positive (ER-positive) or progesterone receptor-positive (PR-positive) breast cancers. These cancers are commonly treated with hormone therapy. Certain targeted therapy drugs can make hormone therapy even more effective, although these targeted drugs might also add to the side effects.

CDK4/6 inhibitors

Palbociclib (Ibrance), **ribociclib (Kisqali)**, and **abemaciclib (Verzenio)** are drugs that block proteins in the cell called cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6. Blocking these proteins in hormone receptor-positive breast cancer cells helps stop the cells from dividing. This can slow cancer growth.

These drugs can be used to treat men with hormone receptor-positive, HER2-negative breast cancer. There are different ways to use these drugs:

- For men with early-stage breast cancer that has spread to the lymph nodes and has a high chance of coming back after surgery, abemaciclib can be given as adjuvant treatment along with tamoxifen or an AI. It is typically given for 2 years.
- Any of these drugs can be given along with an aromatase inhibitor (AI) or fulvestrant to treat advanced breast cancer.
- Abemaciclib can also be used by itself in men with advanced breast cancer who have previously been treated with hormone therapy and chemotherapy.

These drugs are taken as pills, typically once or twice a day.

also called interstitial lung disease or pneumonitis.

PI3K inhibitors

Alpelisib (Piqray) and inavolisib (Itovebi) block a form of the PI3K protein in cancer cells, which can help stop them from growing.

These drugs can be used to treat men with advanced hormone receptor-positive, HER2-negative breast cancer with a *PIK3CA* gene mutation that has grown during or after treatment with hormone therapy. (The *PIK3CA* gene is the gene that tells the cell to make the PI3K protein.) Your doctor will test your blood or tumor for this mutation before starting treatment with one of these drugs.

Alpelisib is used along with the hormone drug fulvestrant.
I 62pI530 gs ()Thormone dru /Ged al gsget2pl the palbicacl gs (seethis mutation)TjQ BT 1 800 1

This drug can be used along with the hormone drug fulvestrant to treat advanced hormone receptor-positive, HER2-negative breast cancer, if the cancer cells have changes in any of the *PIK3CA*, *AKT1*, or *PTEN* genes, and if the cancer has grown during or after treatment with hormone therapy. Your doctor will test your blood or tumor for these mutations before starting treatment with this drug.

This drug is taken as pills, typically twice a day for 4 days, followed by 3 days off each week.

Side effects of capivasertib can include:

- High blood sugar levels: Your cancer care team will check your blood sugar levels before and during your treatment.
- Diarrhea (which may be severe): Tell your cancer team right away if start to have loose stool or diarrhea.
- Skin rash or other skin reactions: Very severe skin reactions, such as rashes with peeling and blistering, are possible and should be reported to a doctor.

Other possible side effects can include nausea, vomiting, mouth sores, skin rash, and changes in certain blood tests.

mTOR inhibitor

Everolimus (Afinitor) is a targeted drug known as an *mTOR inhibitor*. It blocks mTOR, a protein in cells that normally helps them grow and divide. Everolimus may also stop tumors from developing new blood vessels, which can help limit their growth. When used for treating breast cancer, this drug seems to help hormone therapy drugs work better.

This drug is approved to treat advanced hormone receptor-positive, HER2-negative, breast cancer in women who have gone through menopause. It is meant to be used with exemestane (Aromasin) in these women if their cancers have grown while they were being treated with either letrozole or anastrozole (or if the cancer started growing shortly after treatment with these drugs was stopped).

Everolimus is also being studied for use for earlier stage breast cancer and combined with other treatments. Although most of the people with breast cancer in studies of everolimus are women, some studies have included men.

Everolimus is taken as a pill, typically once a day.

Common **side effects of everolimus** include mouth sores, diarrhea, nausea, fatigue, feeling weak or tired, low blood counts, shortness of breath, and cough. Everolimus can also increase blood lipids (cholesterol and triglycerides) and blood sugars, so your doctor will check your blood work periodically while you are on this drug. It can also increase your risk of serious infections, so your doctor will watch you closely for infection while you are on treatment.

Antibody-drug conjugate

An antibody-drug conjugate (ADC) is a monoclonal antibody joined to a chemotherapy drug. The antibody acts like a homing signal by attaching to a specific protein on cancer cells, bringing the chemo directly to them.

Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings the chemo directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)

This ADC can be used to treat advanced hormone receptor-positive, HER2-negative breast cancer, in people who have already received hormone therapy and at least 2 chemo regimens.

This drug is given into a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.

Some common **side effects** of this drug include nausea, vomiting, diarrhea, constipation, feeling tired, rash, loss of appetite, hair loss, low red blood cell counts, and belly pain. Serious side effects can include very low white blood cell counts (with an increased risk of infection), severe diarrhea, and infusion reactions (similar to an allergic reaction) when the drug is infused. Medicines are normally given before each treatment to lower the chances of vomiting and infusion reactions.

Targeted therapy for men with

Olaparib and talazoparib can be used to treat metastatic, HER2-negative breast cancer in patients with a *BRCA* mutation who have already gotten chemotherapy (and hormone therapy if the cancer is hormone receptor-positive).

Only a portion of men with breast cancer have a <u>mutated *BRCA* gene that they are born</u> with³, and which is in all the cells of the body (as opposed to the gene change being acquired and found only in the cancer cells). If you are not known to have a *BRCA* mutation, your doctor will test your blood to be sure you have one before starting treatment with one of these drugs.

These drugs come in pills that are taken once or twice a day.

Side effects can include nausea, vomiting, diarrhea, fatigue, loss of appetite, taste changes, low red blood cell counts (anemia), low platelet counts, low white blood cell counts, belly pain, and muscle and joint pain. Rarely, some people treated with a PARP inhibitor have developed a blood cancer, such as <u>myelodysplastic syndrome</u>⁴ or <u>acute myeloid leukemia (AML)</u>⁵.

Targeted therapy for triple-negative breast cancer

In triple-negative breast cancer (TNBC), the cancer cells don't have estrogen or progesterone receptors, and they make very little or none of the HER2 protein.

Antibody-drug conjugate

An antibody-drug conjugate (ADC) is a monoclonal antibody joined to a chemotherapy drug. The antibody acts like a homing signal by attaching to a specific protein on cancer cells, bringing the chemo directly to them.

Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings the chemo directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)

This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.

Some common **side effects** of this drug include nausea, vomiting, diarrhea, constipation, feeling tired, rash, loss of appetite, hair loss, low red blood cell counts, and belly pain. Serious side effects can include very low white blood cell counts (with an

increased risk of infection), severe diarrhea, and infusion reactions (similar to an allergic reaction) when the drug is infused. Medicines are normally given before each treatment to lower the chances of vomiting and infusion reactions.

More information about targeted therapy

To learn more about how targeted drugs are used to treat cancer, see <u>Targeted Cancer</u> <u>Therapy</u>⁶.

To learn about some of the side effects listed here and how to manage them, see <u>Managing Cancer-related Side Effects</u>⁷.

Hyperlinks

- 1. <u>www.cancer.org/cancer/managing-cancer/treatment-types/biosimilar-</u> <u>drugs/list.html</u>
- 2. <u>www.cancer.org/cancer/types/breast-cancer-in-men/detection-diagnosis-</u> <u>staging/classifying.html</u>
- 3. <u>www.cancer.org/cancer/types/breast-cancer-in-men/causes-risks-prevention/what-</u> <u>causes.html</u>
- 4. <u>www.cancer.org/cancer/types/myelodysplastic-syndrome.html</u>
- 5. <u>www.cancer.org/cancer/types/acute-myeloid-leukemia.html</u>
- 6. www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy.html
- 7. <u>www.cancer.org/cancer/managing-cancer/side-effects.html</u>

References

Bardia A, Mayer IA, Diamond JR, et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. *J Clin Oncol.* 2017;35(19):21412148. doi:10.1200/JCO.2016.70.8297.

Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. *N Engl J Med*. 2012;366: 520529.

Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med.* 2012 Jan 12;366(2):109-19. Epub 2011 Dec 7.

Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. *J Clin Oncol.* 2010 Mar 1;28(7):1124-1130. Epub 2010 Feb 1.

Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. *J Clin Oncol.* 2010 Mar 10;28(8):1301-7. Epub 2010 Feb 8.

Dickler MN et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HRb/HER2_ Metastatic Breast Cancer. *Clin Cancer Res*; 23(17); 5218-5224.

Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol.* 2015;16(1):25-35.

Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med.* 2016;375(20):1925-1936.

Gao et al. *Sci. Signal.* 2013 & Cerami et al. *Cancer Discov.* 2012. Accessed at http://www.cbioportal.org/results/cancerTypesSummary?case_set_id=all&gene_list=PIK 3CA&cancer_study_list=5c8a7d55e4b046111fee2296 on May 29, 2019.

Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med.* 2016;375(18):1738-1748;(suppl).

Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib + letrozole in hormone receptor-positive, HER2negative advanced breast cancer. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 1038.

Morrow M, Burstein HJ, Harris JR. Chapter 79: Malignant Tumors of the Breast. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications. *Breast Cancer (Dove Med Press)*. 2015;7: 111–123.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology:

Breast Cancer. Version 3.2017. Accessed at www.nccn.org on January 18, 2018.

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med.* 2012 Nov 8;367(19):1783-91. Epub 2012 Oct 1.

Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2 Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology 2017 35:25, 2875-2884.

Wolff AC, Domchek SM, Davidson NE, Sacchini V, McCormick B. Chapter 91: Cancer

Immunotherapy for Breast Cancer in Men

Pembrolizumab (Keytruda) for breast cancer

Pembrolizumab (Keytruda) is a drug that targets PD-1, a protein on immune system cells called *T cells* that normally help keep these cells from attacking other cells in the body. By blocking PD-1, these drugs boost the immune response against breast cancer cells. This can often shrink tumors.

It can be used with chemotherapy to treat <u>triple-negative breast cancer</u>¹ (that makes the PD-L1 protein) that:

- has come back (recurred) locally but can't be removed by surgery and hasn't been treated with chemotherapy this time OR
- has spread to other parts of the body and has not been treated with chemotherapy this time.

This drug is given as an intravenous (IV) infusion, typically every 3 or 6 weeks.

Possible side effects of immune checkpoint inhibitors

Side effects of these drugs can include fatigue, cough, nausea, skin rash, poor appetite, constipation, and diarrhea.

Other, more serious side effects occur less often.

Infusion reactions: Some people might have an infusion reaction while getting these drugs. This is like an allergic reaction, and can include fever, chills, flushing of the face, rash, itchy skin, feeling dizzy, wheezing, and trouble breathing. It's important to tell your doctor or nurse right away if you have any of these symptoms while getting these drugs.

Autoimmune reactions: These drugs remove one of the safeguards on the body's immune system. Sometimes the immune system starts attacking other parts of the body, which can cause serious or even life-threatening problems in the lungs, intestines, liver, hormone-making glands, kidneys, or other organs.

It's very important to report any new side effects to your health care team quickly. If serious side effects do occur, treatment may need to be stopped and you may get high doses of corticosteroids to suppress your immune system.

More information about immunotherapy

To learn more about how drugs that work on the immune system are used to treat

cancer, see <u>Cancer Immunotherapy</u>².

To learn about some of the side effects listed here and how to manage them, see <u>Managing Cancer-related Side Effects</u>³.

Hyperlinks

- 1. <u>www.cancer.org/cancer/types/breast-cancer-in-men/detection-diagnosis-</u> <u>staging/classifying.html</u>
- 2. www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy.html
- 3. <u>www.cancer.org/cancer/managing-cancer/side-effects.html</u>

References

Jagsi R, King TA, Lehman C, Morrow M, Harris JR, Burstein HJ. Chapter 79: Malignant Tumors of the Breast. In: DeVita VT, Lawrence TS, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Breast Cancer. Version 2.2019. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf on July 22, 2019.

Schmidt P, Adams S, Rugo HS, Scheeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *N Engl J Med.* 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.

Last Revised: December 4, 2020

Treatment of Breast Cancer in Men, by Stage

- Stage 0 (ductal carcinoma in situ)
- Stage I
- Stage II
- Stage III
- Stage IV (metastatic)
- Recurrent cancer

This information is based on AJCC Staging systems prior to 2018 which were primarily based on tumor size and lymph node status. Since the updated staging system for breast cancer now also includes the ER, PR and HER2 status, the stages may be higher or lower than previous staging systems. Whether or not treatment strategies will change with this new staging system are yet to be determined. You should discuss your stage and treatment options8 gs (You shouh72 517.72 Tm 0 0 0e III)Tj 0 g ET q BT 1 0 ad dis. Tf 0 0

remaining breast tissue.

Sometimes DCIS can contain an area of invasive cancer. The chance that an area of DCIS contains invasive cancer goes up with tumor size and how fast the cancer is growing. If there is concern of invasive cancer, the lymph nodes under the arm may be checked for spread, most often with a sentinel lymph node biopsy. If cancer cells are found in the sentinel lymph node, it means the tumor must contain some invasive cancer, and the man will be treated based on his invasive cancer stage.

Stage I

These cancers are still relatively small and either have not spread to the lymph nodes (N0) or there is a tiny area of cancer spread in the sentinel lymph node (N1mi).

The main treatment for stage I breast cancer is to remove it with surgery. This is usually done by mastectomy, but breast-conserving surgery (BCS) might occasionally be an option. If breast-conserving surgery is done, it is usually followed by radiation therapy.

The lymph nodes under the arm will be checked for cancer spread, either with an axillary lymph node dissection (ALND) or sentinel node biopsy (SLNB). If the sentinel lymph node contains cancer, a full ALND may be needed, depending on the size of the cancer in the lymph node as well as what other treatment is planned.

Hormone ya q 0.9012 T7.is usually followed by

the arm will be checked for cancer spread, either with an axillary lymph node dissection (ALND) or sentinel lymph node biopsy. If the sentinel lymph node contains cancer, a full ALND may be needed, depending on the size of the cancer in the lymph node as well as what other treatment is planned.

Radiation therapy may be given after surgery if the tumor is large or if it is found to have spread to several lymph nodes. Radiation therapy lowers the risk of the cancer coming back (recurrence).

The drugs used will depend on the man's age and the tumor's hormone-receptor status and HER2 status. They may include:

cancers for at least 5 years.

Stage IV (metastatic)

Stage IV cancers have spread beyond the breast and nearby lymph nodes to other parts of the body. Breast cancer most commonly spreads to the bones, liver, and lungs.

Treatment for advanced breast cancer can often shrink or slow the growth of the cancer (sometimes for many years), but after a time it may stop working. Further treatment at this point depends on several factors, including previous treatments, where the cancer is located, and a man's age, general health, and desire to continue getting treatment.

Progression while on hormone therapy: For hormone receptor-positive cancers that were being treated with hormone therapy, switching to another type of hormone therapy is sometimes helpful. Another option might be a hormone drug along with a targeted therapy drug. If this isn't helpful, chemo is usually the next step.

Progression while on chemotherapy: For cancers that are no longer responding to one chemo regimen, trying another may be helpful. Many different drugs and combinations can be used to treat breast cancer. However, each time a cancer progresses during treatment it becomes less likely that further treatment will have an effect.

For breast cancers that are considered <u>HER2-low</u>⁶ and have spread to distant sites after trying chemotherapy, the antibody-drug conjugate fam-trastuzumab deruxtecan (Enhertu) might be an option.

For advanced hormone receptor-positive, HER2-negative breast cancer or for <u>triple-negative breast cancer</u>⁷ in which at least 2 other chemo treatments have been tried, the antibody-drug conjugate sacituzumab govitecan (Trodelvy) might be an option.

Progression while getting HER2 drugs: HER2-positive cancers that no longer respond to trastuzumab may respond to other drugs that target the HER2 protein (sometimes along with chemo or hormone therapy drugs). Some options might include:

- Pertuzumab (Perjeta) with chemo and trastuzumab
- Ado-trastuzumab emtansine (Kadcyla)
- Fam-trastuzumab deruxtecan (Enhertu)
- Margetuximab (Margenza) with chemo
- Lapatinib (Tykerb) and the chemo drug capecitabine
- Lapatinib and an aromatase inhibitor (for hormone receptor-positive cancers)
- Neratinib (Nerlynx) and the chemo drug capecitabine (this combination can be helpful for cancers that have spread to the brain)
- Tucatinib (Tukysa), trastuzumab, and the chemo drug capecitabine (this combination can be helpful for cancers that have spread to the brain)

Because current treatments are very unlikely to cure advanced breast cancer, if you are

in otherwise good health, you may want to think about taking part in a <u>clinical</u> <u>trial</u>⁸ testing newer treatments. You can also read about living with later-stage cancer in <u>Advanced Cancer</u>, <u>Metastatic Cancer</u>, and <u>Bone Metastasis</u>⁹.

Recurrent cancer

For some men, breast cancer may come back after treatment – sometimes years later. This is called a *recurrence*. **Recurrence can be local (in the same breast or in the surgery scar), regional (in nearby lymph nodes), or in a distant area.** If cancer is found in the opposite breast but nowhere else in the body, it is not a recurrence—it's a new cancer that requires its own treatment.

Treating local recurrence: This includes cancer coming back in the breast or in the chest wall (near the mastectomy scar). If a patient has a local recurrence and no evidence of distant metastases, it might still be cured. Treatment depends on what other treatments have been given already. The treatment for local recurrence may be additional surgery followed by radiation therapy. If the area has already been treated with radiation, it might not be possible to give more radiation to the area without damaging nearby tissues.

Hormone therapy, chemo, trastuzumab, or some combination of these may be used after surgery and/or radiation therapy.

For people with <u>triple-negative breast cancer</u>¹⁰ that has come back locally, cannot be removed with surgery, and makes the PD-L1 protein, immunotherapy with the drug pembrolizumab along with chemotherapy might be an option. If at least 2 other drug regimens have already been tried, the <u>antibody-drug conjugate</u> sacituzumab govitecan (Trodelvy) might be an option as well.

Treating regional recurrence: When breast cancer comes back in nearby lymph nodes (such as those under the arm or around the collar bone), it is treated by removing those lymph nodes. This may be followed by radiation treatments aimed at the area.

Systemic treatment (such as hormone therapy, chemo, targeted therapy, or some combination of these) may be used after surgery and/or radiation therapy.

Treating distant recurrence: Men who have a recurrence in places such as the bones, lungs, brain, etc., are often treated the same way as those found to have stage IV breast cancer with spread to these organs when they were first diagnosed (see above). The only difference is that treatment may be affected by the previous treatments a man has had.

¹⁴Jain S and Gradishar WJ. Chapter 61: Male Breast Cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. *Diseases of the Breast*. 5th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 2014.

Morrow M, Burstein HJ, Harris JR. Chapter 79: Malignant Tumors of the Breast. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Breast Cancer. Version 3.2017. Accessed at www.nccn.org on January 18, 2018.

Wolff AC, Domchek SM, Davidson NE, Sacchini V, McCormick B. Chapter 91: Cancer of the Breast. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. *Abeloff's Clinical Oncology*. 5th ed. Philadelphia, Pa: Elsevier; 2014.

Last Revised: February 6, 2023

Questions to Ask Your Doctor About Breast Cancer in Men

- When you're told you have breast cancer
- When deciding on a treatment plan
- If you need surgery
- During treatment
- After treatment

It's important to be able to have frank, open discussions with your cancer care team. They want to answer all of your questions, so that you can make informed treatment and life decisions.

Here are some questions that you can use to help better understand your cancer and your treatment options. Don't be afraid to take notes and tell the doctors or nurses when you don't understand what they're saying. You might want to bring another person with you when you see your doctor and have them take notes to help you remember what was said.

Not all of these questions will apply to you, but they should help get you started. Be sure to write down some questions of your own. For instance, you might want more information about recovery times or you may want to ask about nearby or online support groups where you can talk with other men going through similar situations. You may also want to ask if you qualify for any <u>clinical trials</u>¹.

Keep in mind that doctors aren't the only ones who can give you information. Other

- Can I exercise during treatment? If so, what kind of exercise should I do, and how often?
- Can you suggest a mental health professional I can see if I start to feel overwhelmed, depressed, or distressed?
- Will I need special tests, such as imaging scans or blood tests? How often?

After treatment

- What are the chances my cancer might come back? What will we do if that happens?
- What type of follow-up will I need after treatment?
- Will I need a special diet after treatment?
- Are there any limits on what I can do?
- Am I at risk for lymphedema?
- What can I do to reduce my risk for lymphedema?
- What should I do if I notice swelling in my arm?
- What other symptoms should I watch for? What kind of exercise should I do now?
- What type of follow-up will I need after treatment?
- How often will I need to have follow-up exams, blood tests, or imaging tests?
- How will we know if the cancer has come back? What should I watch for?

Hyperlinks

- 1. <u>www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-</u> <u>trials.html</u>
- 2. <u>www.cancer.org/cancer/managing-cancer/finding-care/the-doctor-patient-</u> relationship.html
- 3. <u>www.cancer.org/cancer/managing-cancer/finding-care/seeking-a-second-opinion.html</u>

Last Revised: April 27, 2018

Written by

The American Cancer Society medical and editorial content team (<u>https://www.cancer.org/cancer/acs-medical-content-and-news-staff.html</u>)

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.

_